Bone Biologics Announces 1-for-6 Reverse Stock Split
Reverse Stock Split Announcement: Bone Biologics Corporation plans to implement a reverse stock split at a ratio of 1-for-6, effective June 10, 2025, following approval from stockholders.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing products based on the Nell-1 protein with strategic partners.
Trade with 70% Backtested Accuracy
Analyst Views on BBLGW
No data
About the author
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Filed: Bone Biologics Corporation has filed a patent application for its novel NELL-1 protein, aimed at treating bone conditions, which could enhance its intellectual property portfolio and support clinical development efforts.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is collaborating with strategic partners to advance the research and development of its products.
Bone Biologics Announces 1-for-6 Reverse Stock Split
Reverse Stock Split Announcement: Bone Biologics Corporation plans to implement a reverse stock split at a ratio of 1-for-6, effective June 10, 2025, following approval from stockholders.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing products based on the Nell-1 protein with strategic partners.
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Appointment of New Board Member: Bone Biologics Corporation has appointed Phillip T. Meikle to its board of directors, succeeding Don R. Hankey, who retired after seven years. Mr. Meikle brings over 30 years of experience in the orthopedic and spine industry.
Company Focus and Future Plans: Bone Biologics is concentrating on developing its lead product candidate, NB1, for spinal fusion patients, leveraging Mr. Meikle's extensive industry knowledge and relationships to enhance their efforts in regenerative medicine for bone.
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Warrant Exercise Agreement: Bone Biologics Corporation has entered into an agreement to exercise existing warrants for 781,251 shares of common stock at $2.43 per share, with new unregistered warrants being issued for an additional 1,562,502 shares at an exercise price of $2.00 each.
Use of Proceeds: The company expects to raise approximately $2.1 million from this transaction, which will be used to fund clinical trials, extend its patent portfolio, and support general corporate purposes.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Announcement: Bone Biologics Corporation has filed a patent application for its NELL-1 protein, aimed at treating bone conditions, which is seen as a significant step in enhancing treatments for spine fusion patients.
Company Overview and Future Plans: The company focuses on regenerative medicine for bone, particularly in spinal fusion, and aims to strengthen its intellectual property portfolio while advancing clinical development programs.
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Filed: Bone Biologics Corporation has filed a patent application for its novel NELL-1 protein, aimed at treating bone conditions, which could enhance its intellectual property portfolio and support clinical development efforts.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is collaborating with strategic partners to advance the research and development of its products.
Bone Biologics Announces 1-for-6 Reverse Stock Split
Reverse Stock Split Announcement: Bone Biologics Corporation plans to implement a reverse stock split at a ratio of 1-for-6, effective June 10, 2025, following approval from stockholders.
Company Overview: Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing products based on the Nell-1 protein with strategic partners.
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
Appointment of New Board Member: Bone Biologics Corporation has appointed Phillip T. Meikle to its board of directors, succeeding Don R. Hankey, who retired after seven years. Mr. Meikle brings over 30 years of experience in the orthopedic and spine industry.
Company Focus and Future Plans: Bone Biologics is concentrating on developing its lead product candidate, NB1, for spinal fusion patients, leveraging Mr. Meikle's extensive industry knowledge and relationships to enhance their efforts in regenerative medicine for bone.
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Warrant Exercise Agreement: Bone Biologics Corporation has entered into an agreement to exercise existing warrants for 781,251 shares of common stock at $2.43 per share, with new unregistered warrants being issued for an additional 1,562,502 shares at an exercise price of $2.00 each.
Use of Proceeds: The company expects to raise approximately $2.1 million from this transaction, which will be used to fund clinical trials, extend its patent portfolio, and support general corporate purposes.
Bone Biologics Files Patent Application for Bone Regeneration Technology
Patent Application Announcement: Bone Biologics Corporation has filed a patent application for its NELL-1 protein, aimed at treating bone conditions, which is seen as a significant step in enhancing treatments for spine fusion patients.
Company Overview and Future Plans: The company focuses on regenerative medicine for bone, particularly in spinal fusion, and aims to strengthen its intellectual property portfolio while advancing clinical development programs.
